| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Martynoside targets estrogen receptors (ERα and ERβ), exhibiting both estrogenic and antiestrogenic properties. It is a potent antiestrogen in MCF-7 cells, increasing IGFBP3 levels. Martynoside protects bone marrow cells from 5-fluorouracil-induced cell death and inflammation by down-regulating the TNF signaling pathway. It also exhibits antioxidant activity via direct radical quenching.
|
|---|---|
| ln Vitro |
In vitro, martynoside is a potent antiestrogen in MCF-7 cells, increasing IGFBP3 levels. It protects ex vivo bone marrow cells from 5-fluorouracil (5-FU)-induced cell death and inflammation response by down-regulating the TNF signaling pathway. Martynoside also exhibits anticancer, cytotoxic, hematopoietic, and antioxidant activities. It has been shown to exhibit both estrogenic and antiestrogenic properties.
|
| ln Vivo |
Martynoside is not a pharmacologically approved drug but has been studied for its potential therapeutic applications. It has the potential of antagonizing sports anemia, and the mechanism might be related to preventing red blood cells from free radical damage. Martynoside's ability to modulate estrogen receptors suggests its potential use as a natural selective estrogen receptor modulator (SERM), which could be beneficial in treating conditions like osteoporosis. It has not been evaluated in clinical trials.
|
| Enzyme Assay |
In vitro assays for martynoside typically involve cell viability and signaling pathway studies. A standard protocol for antiestrogenic activity involves culturing MCF-7 breast cancer cells in estrogen-free media and treating them with varying concentrations of martynoside (typically 1-100 µM). IGFBP3 levels are measured by ELISA or Western blotting. For bone marrow protection studies, bone marrow cells are treated with 5-fluorouracil in the presence or absence of martynoside (50 µg/mL), and cell viability is assessed. TNF signaling is measured by Western blotting.
|
| Cell Assay |
In vitro cell culture experiments with martynoside typically involve MCF-7 breast cancer cells or bone marrow cells. MCF-7 cells are cultured in appropriate media and treated with martynoside at concentrations ranging from 1-100 µM for 24-72 hours. IGFBP3 levels and estrogen receptor signaling are measured. For bone marrow protection studies, cells are treated with 5-fluorouracil in the presence or absence of martynoside, and cell viability is assessed using MTT assays.
|
| Animal Protocol |
In vivo animal studies with martynoside are not well documented, as it is primarily a research compound. If conducted, typical protocols for hematopoietic protection would involve administering martynoside to mice treated with 5-fluorouracil and measuring bone marrow cell counts and hematopoietic recovery. However, such studies are not standard for this compound.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of martynoside are not characterized, as it is not a drug substance. Based on its physicochemical properties (molecular weight 652.64), the compound would be expected to have moderate oral bioavailability. The compound is soluble in DMSO. No formal pharmacokinetic studies have been conducted.
|
| Toxicity/Toxicokinetics |
Martynoside may cause skin and eye irritation. Standard laboratory safety precautions should be followed when handling this compound, including the use of gloves, safety glasses, and working in a fume hood. The compound should be stored in a cool, dry place away from light and moisture. No acute toxicity data are available. The compound is not intended for drug, household, or other uses.
|
| References |
|
| Additional Infomation |
Martynoside has been reported to have been found in thornless calyx flowers, Rehmannia glutinosa, and other organisms with available data.
Martynoside is an active glycoside extracted from Rehmannia glutinosa. It exhibits antioxidant, antiestrogenic, anticancer, cytotoxic, hematopoietic, and anti-metastatic properties. Martynoside protects bone marrow cells from 5-fluorouracil-induced cell death. It has not undergone clinical trials and is not approved as a pharmaceutical. |
| Molecular Formula |
C31H40O15
|
|---|---|
| Molecular Weight |
652.64
|
| Exact Mass |
652.236
|
| CAS # |
67884-12-2
|
| PubChem CID |
5319292
|
| Appearance |
White to off-white solid powder
|
| Density |
1.5±0.1 g/cm3
|
| Boiling Point |
865.1±65.0 °C at 760 mmHg
|
| Flash Point |
274.9±27.8 °C
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
| Index of Refraction |
1.641
|
| LogP |
2.96
|
| Hydrogen Bond Donor Count |
7
|
| Hydrogen Bond Acceptor Count |
15
|
| Rotatable Bond Count |
13
|
| Heavy Atom Count |
46
|
| Complexity |
968
|
| Defined Atom Stereocenter Count |
10
|
| SMILES |
C[C@H]1[C@@H]([C@H]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H](O[C@@H]([C@H]2OC(=O)/C=C/C3=CC(=C(C=C3)O)OC)CO)OCCC4=CC(=C(C=C4)OC)O)O)O)O)O
|
| InChi Key |
WLWAYPFRKDSFCL-CNMJWYMJSA-N
|
| InChi Code |
InChI=1S/C31H40O15/c1-15-24(36)25(37)26(38)31(43-15)46-29-27(39)30(42-11-10-17-5-8-20(40-2)19(34)12-17)44-22(14-32)28(29)45-23(35)9-6-16-4-7-18(33)21(13-16)41-3/h4-9,12-13,15,22,24-34,36-39H,10-11,14H2,1-3H3/b9-6+/t15-,22+,24-,25+,26+,27+,28+,29+,30+,31-/m0/s1
|
| Chemical Name |
[(2R,3R,4R,5R,6R)-5-hydroxy-6-[2-(3-hydroxy-4-methoxyphenyl)ethoxy]-2-(hydroxymethyl)-4-[(2S,3R,4R,5R,6S)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxyoxan-3-yl] (E)-3-(4-hydroxy-3-methoxyphenyl)prop-2-enoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: 25 mg/mL (38.31 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.5 mg/mL (3.83 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.5 mg/mL (3.83 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 25.0 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5322 mL | 7.6612 mL | 15.3224 mL | |
| 5 mM | 0.3064 mL | 1.5322 mL | 3.0645 mL | |
| 10 mM | 0.1532 mL | 0.7661 mL | 1.5322 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
